ArticleCancers2025

Pharmacologic Targeting of miR29b with Bortezomib and Sorafenib to Improve Decitabine Sensitivity in Patients with Acute Myeloid Leukemia: Results from a Phase 1 Dose-Escalation Trial.

Shivani Handa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.